Seeking Alpha

Perfuse Therapeutics Announces Positive Results from the Completed Phase 1/2a Clinical Trial of PER-001 Intravitreal Implant in Patients with Glaucoma

– A single intravitreal administration of PER-001 improved both visual function and anatomic structure compared to control at 24 weeks – – These data support the potential of PER-001 as the first ...
Seeking Alpha

Iveric Bio Receives U.S. FDA Approval for IZERVAY™ (avacincaptad pegol intravitreal solution), a New Treatment for Geographic Atrophy

IZERVAY is the only approved GA treatment with a statistically significant reduction in the rate of GA progression at the 12-month primary endpoint across two Phase 3 clinical trials IZERVAY slowed ...
Healio

Patients with geographic atrophy require careful screening, opportunity for treatment

Read this issue’s cover story titled “Specialists navigate changing, challenging landscape of geographic atrophy management.” ...
Nasdaq

Astellas Receives Permanent J-code for IZERVAY™ (avacincaptad pegol intravitreal solution) for Geographic Atrophy

NORTHBROOK, Ill., March 26, 2024 /PRNewswire/ -- Iveric Bio, An Astellas Company (TSE: 4503, President and CEO: Naoki Okamura, "Astellas"), today announced the U.S. Centers for Medicare and Medicaid ...
MedPage Today

Gene Therapies for Neovascular AMD Continue to Show Promise

STOCKHOLM -- Two VEGF-targeting gene therapies for neovascular age-related macular degeneration (nAMD) substantially reduced treatment burden while preserving visual acuity, according to results ...